Roche ’s OCREVUS subcutaneous injection receives EU CHMP positive opinion for relapsing and primary progressive multiple sclerosis
If approved, OCREVUS subcutaneous (SC) would be the first and only twice-a-year, 10-minute injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the EUOCREVUS SC will be a new, faster way of administering OCREVUS with a comparable efficacy and safety profile tothe well-established intravenous (IV) infusionOCREVUS SC has the potential to expand treatment optionsto centres without IV infrastructure or with IV constraintsBasel, 29 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use...
Source: Roche Investor Update - April 29, 2024 Category: Pharmaceuticals Source Type: news
PET reveals ‘smoldering’ brain inflammation in patients treated for MS
This study tells us something new about the disease and may be giving us an important clue as to what is driving disease progression in patients,” noted Rohit Bakshi, MD, a co-author on the paper.
Ultimately, the study validates the use of F-18 PBR06 PET scans in these patients, with the tracer providing a longer half-life life than current tracers, according to the group. This allows extended imaging acquisition times to measure TSPO as a biomarker, the team wrote.
“This is a new approach that is potentially going to be very helpful for the field, for research, and hopefully for clinical use,” the researchers conc...
Source: AuntMinnie.com Headlines - April 29, 2024 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
Jamie-Lynn Sigler Says the ‘Sopranos’ Set Physician Told Her Not to Disclose MS Diagnosis
Jamie-Lynn Sigler says she was told not to disclose her multiple sclerosis diagnosis on The Sopranos by the set physician. While appearing on Sophia Bush’s podcast Work in Progress, the actress shared that she was diagnosed with multiple sclerosis at 20-years-old, a year after receiving a Lyme…#jamielynnsigler #sopranos #sophiabushs #workinprogress #lyme #ajdiscala #jamesgandolfini #nt #ediefalco #hbo (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2024 Category: Consumer Health News Source Type: news
Better Scans Spot Hidden Inflammation in MS Patients
FRIDAY, April 26, 2024 -- Advanced scanning techniques can find hidden inflammation in the brains of multiple sclerosis (MS) patients, a new study shows.This “smoldering” inflammation detected by positron emission tomography (PET) brain scans... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 26, 2024 Category: General Medicine Source Type: news
Right brain: the unraveling - Michaelson NM.
"The Unraveling" is a personal reflection from my perspective as a new fellow in Multiple Sclerosis/Neuroimmunology on the impact of multiple sclerosis on patients and their loved ones. I compare my more recent patient encounters with past experiences work... (Source: SafetyLit)
Source: SafetyLit - April 26, 2024 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news
The association of fear of falling and falls with sedentary behavior in people with multiple sclerosis - Farber AE, Menascu S, Kalron A.
OBJECTIVE: Sedentary behavior, falls, and fear of falling (FoF) are specific concerns for people with MS (pwMS). Considering the relatively high incidence and potential linkage, it is surprising that this triple relationship has as yet not been extensively... (Source: SafetyLit)
Source: SafetyLit - April 25, 2024 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Investor Update - April 24, 2024 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19
Group sales grew by 2%1 at constant exchange rates (CER) (-6% in CHF), driven by the strong growth of newer medicines and diagnostics. Excluding COVID-19-related products, sales increased by 7%. Going forward, there will be no further material impact of COVID-19 sales declineDue to the appreciation of the Swiss franc against most currencies,saleswere 6% lower when reported in CHFPharmaceuticals Divisionbase business2 grew by 7%, driven by strong sales of medicines to treat severe diseases, such as Vabysmo (eye diseases), Phesgo (breast cancer), Ocrevus (multiple sclerosis), Polivy (blood cancer) and Hemlibra (haemophilia A...
Source: Roche Media News - April 24, 2024 Category: Pharmaceuticals Source Type: news
Alzheimer's Drug Skepticism; Safeguarding Brain Data; Benefits of Stimulating Jobs
(MedPage Today) -- Physicians treating Alzheimer's patients discussed why they're hesitant to prescribe lecanemab (Leqembi). (Reuters)
Researchers reviewed the role of neurofilament proteins in multiple sclerosis (MS), Alzheimer's disease, frontotemporal... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 23, 2024 Category: Neurology Source Type: news
Hyperfine highlights abstracts to be presented at ISMRM 2024
Hyperfine is highlighting 17 ultralow-field MRI-related abstracts to be presented at the 2024 International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting, to be held from May 4 to 9 in Singapore.
The abstracts span a variety of use cases, including two that highlight the utility of brain images acquired with the ultralow-field Swoop Portable MR Imaging system to aid physicians in screening for various biomarkers and monitoring disease progression unique to neurodegenerative diseases. These include Alzheimer’s disease and multiple sclerosis. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 23, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Novel Drug Made of Gold Nanocrystals Appears Safe in Multiple Sclerosis
(MedPage Today) -- DENVER -- An oral suspension of clean-surfaced gold nanocrystals known as CNM-Au8 was safe and well-tolerated in patients with stable relapsing-remitting multiple sclerosis (MS) and chronic optic neuropathy, the long-term open... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 22, 2024 Category: Neurology Source Type: news
Multiple Sclerosis Predicted by Autoantibody Signature
(MedPage Today) -- A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms appeared, blood samples showed.
A distinct set of autoantibodies emerged in approximately 10% of MS... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - April 20, 2024 Category: Neurology Source Type: news
ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data ICI Tx in MS Patients With Comorbid Cancer: Reassuring Data
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 19, 2024 Category: Cancer & Oncology Tags: Neurology & Neurosurgery News Source Type: news
Blood Test Might Someday Diagnose Early MS
FRIDAY, April 19, 2024 -- An early marker of multiple sclerosis could help doctors figure out who will eventually fall prey to the degenerative nerve disease, a new study says.In one in 10 cases of MS, the body begins producing a distinctive set of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 19, 2024 Category: General Medicine Source Type: news
Ocrelizumab Trial Fills Research Gap for Black, Hispanic MS Patients
(MedPage Today) -- DENVER -- Among Black/African American and Hispanic/Latino patients with relapsing multiple sclerosis (MS) in the phase IV CHIMES trial, half achieved a combined measure for no evidence of disease activity (NEDA) with ocrelizumab... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 18, 2024 Category: American Health Source Type: news
